<DOC>
	<DOCNO>NCT00043316</DOCNO>
	<brief_summary>The purpose research study evaluate safety effectiveness Interferon gamma-1b ( IFN-g 1b ) lung function give patient cystic fibrosis inhalation ( breathed lung ) three time week 12 week . The FDA approve Interferon gamma-1b use cystic fibrosis patient , condition examine study .</brief_summary>
	<brief_title>Interferon Gamma-1b Inhalation Treatment Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Key inclusion criterion : At least 12 year age Diagnosis cystic fibrosis mild moderate pulmonary impairment Must receive ongoing chronic treatment TOBI ( inhaled tobramycin ) OR receive ongoing chronic treatment TOBI use TOBI inhale antibiotic within 4 week prior study drug administrationÂ· Other specific diagnostic indicator CF factor must meet minimum requirement .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>cystic fibrosis</keyword>
	<keyword>pulmonary impairment</keyword>
</DOC>